Urology
The tuberculosis vaccine Bacille Calmette-Guérin (BCG), introduced in the 1920s, contains attenuated pathogens of bovine tuberculosis. In studies in the 1970s, BCG was shown to be effective against bladder cancer as well, one of the most common tumour diseases in Europe. BCG triggers an immune reaction that is not specifically directed against the tumour but activates the body's immune system to eliminate the cancer cells.
Instillation therapies in non-muscle invasive bladder cancer (NMIBC) have a long tradition at medac. With two well-established medications, we provide a dual first-line treatment concept for the adjuvant treatment of NMIBC. Powered by the needs of the users and to increase their personal safety, our experts developed the first closed instillation system on the market in 1988.
Today our system comes as standard with our compounds and it is highly regarded for its ease of use and safety by healthcare professionals from all over the world.
By continually developing our expertise over many years, we have been able to reliably serve the undersupplied NMIBC market with preparations for all risk classes, making our products available to patients in need.
